Sign Out
Severe eosinophilic asthma: Nucala is indicated as an add-on treatment for severe refractory eosinophilic asthma in adults and adolescents aged 12 years and older (see Pharmacology: Pharmacodynamics under Actions).
Chronic rhinosinusitis with nasal polyps (CRSwNP): Nucala is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adult patients with severe CRSwNP for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control.
Eosinophilic granulomatosis with polyangiitis (EGPA): Nucala is indicated as an add-on treatment for adult patients with relapsing-remitting or refractory eosinophilic granulomatosis with polyangiitis (EGPA).
Hypereosinophilic syndrome (HES): Nucala is indicated as an add-on treatment for adult patients with inadequately controlled hypereosinophilic syndrome without an identifiable non-haematologic secondary cause (see Pharmacology: Pharmacodynamics under Actions).
